LifeMD
LFMD
Market cap $197M

4.58 USD

-0.18

3.78%

At close Oct 17, 4:00 PM EDT

After hours

4.58

+0.00

0.00%

1 day

-3.78%

5 days

8.79%

1 month

-11.92%

3 months

-32.15%

6 months

-53.60%

Year to date

-45.67%

1 year

-32.35%

5 years

-41.66%

About: LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.

Employees: 232

Healthcare Offices & Clinics of Doctors of Medicine

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 25

17% more funds holding

Funds holding: 88 [Q1] → 103 (+15) [Q2]

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

1.38% more ownership

Funds ownership: 37.69% [Q1] → 39.06% (+1.38%) [Q2]

3% less call options, than puts

Call options by funds: $1.02M | Put options by funds: $1.05M

29% less capital invested

Capital invested by funds: $156M [Q1] → $111M (-$45M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

228%

upside

Avg. target

$15

228%

upside

High target

$15

228%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Sarah James 47% 1-year accuracy 65 / 137 met price target	228%upside $15	Overweight Reiterated	20 Sept 2024
Cantor Fitzgerald Sarah James 47% 1-year accuracy 65 / 137 met price target	228%upside $15	Overweight Reiterated	20 Aug 2024
Cantor Fitzgerald Sarah James 47% 1-year accuracy 65 / 137 met price target	228%upside $15	Overweight Reiterated	9 Aug 2024

See Analyst Rankings

Financial journalist opinion

LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD: Selling WorkSimpli Could Be A Catalyst

LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and GLP1 offerings show significant potential, with the stock priced at 14x forward EBITDA. I have revised my price target from $20 to $15 per share by summer 2025, due to management's credibility issues and uncertainties in GLP1 prospects.

LifeMD: Selling WorkSimpli Could Be A Catalyst

LifeMD to Participate in Three Investor Conferences During September

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September:

LifeMD to Participate in Three Investor Conferences During September

LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript

LifeMD, Inc. (NASDAQ:LFMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial Officer Conference Call Participants David Larsen – BTIG Steve Dechert – KeyBanc William Wood – B. Riley Securities Sarah James – Cantor Yi Chen – H.C.

LifeMD, Inc. (LFMD) Q2 2024 Earnings Call Transcript

Zacks Investment Research

LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago.

LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates

LifeMD Reports Second Quarter 2024 Results

Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67% Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000 Weight management subscribers exceeded 60,000 as of June 30, 2024 Adjusted EBITDA increased 44% to $2.5 million Cash of $35.7 million as of June 30, 2024, and positive net cash flow in three of the last four quarters Conference call begins at 4:30 p.m. Eastern time today NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2024.

LifeMD Reports Second Quarter 2024 Results

LifeMD: High Growth GLP-1 Telehealth Play At A Discount

LifeMD is positioned as a high-growth telehealth play with a focus on GLP-1 weight management treatments. The company is guiding for 35% revenue growth in 2024. Its core telehealth business is expected to grow at least 43%. Non-core software subsidiary WorkSimpli may be spun off in the next 6 to 12 months, while the company is on track for GAAP profitability next year.

LifeMD: High Growth GLP-1 Telehealth Play At A Discount

3 Overlooked Telehealth Stocks Poised for a Comeback

Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032.

3 Overlooked Telehealth Stocks Poised for a Comeback

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD/LFMDP), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare

Identifying investment opportunities in the healthcare sector involves research on trends and next-gen tech. LifeMD offers telehealth services and weight management programs, positioned for growth in the underserved obesity market. Risks include regulatory changes, competition, cash position, and the potential need for additional funding.

LifeMD: Pairing GLP-1 Agonists With Virtual Healthcare

See News Rankings

Charts implemented using Lightweight Charts™